JP2021512929A5 - - Google Patents

Info

Publication number
JP2021512929A5
JP2021512929A5 JP2020542955A JP2020542955A JP2021512929A5 JP 2021512929 A5 JP2021512929 A5 JP 2021512929A5 JP 2020542955 A JP2020542955 A JP 2020542955A JP 2020542955 A JP2020542955 A JP 2020542955A JP 2021512929 A5 JP2021512929 A5 JP 2021512929A5
Authority
JP
Japan
Prior art keywords
faah
inhibitor
pharmaceutical composition
composition according
targets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020542955A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512929A (ja
Filing date
Publication date
Priority claimed from GBGB1802326.7A external-priority patent/GB201802326D0/en
Application filed filed Critical
Publication of JP2021512929A publication Critical patent/JP2021512929A/ja
Publication of JP2021512929A5 publication Critical patent/JP2021512929A5/ja
Pending legal-status Critical Current

Links

JP2020542955A 2018-02-13 2019-02-12 Ｆａａｈ偽遺伝子の遺伝子療法 Pending JP2021512929A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1802326.7A GB201802326D0 (en) 2018-02-13 2018-02-13 Gene therapy
GB1802326.7 2018-02-13
PCT/GB2019/050368 WO2019158909A1 (en) 2018-02-13 2019-02-12 Gene therapy of the faah pseudogene

Publications (2)

Publication Number Publication Date
JP2021512929A JP2021512929A (ja) 2021-05-20
JP2021512929A5 true JP2021512929A5 (https=) 2022-02-21

Family

ID=61731413

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020542955A Pending JP2021512929A (ja) 2018-02-13 2019-02-12 Ｆａａｈ偽遺伝子の遺伝子療法

Country Status (8)

Country Link
US (1) US12241066B2 (https=)
EP (1) EP3752608B1 (https=)
JP (1) JP2021512929A (https=)
CN (1) CN112088214A (https=)
AU (1) AU2019221798A1 (https=)
CA (1) CA3090617A1 (https=)
GB (1) GB201802326D0 (https=)
WO (1) WO2019158909A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022018638A1 (en) 2020-07-21 2022-01-27 Crispr Therapeutics Ag Genome-editing compositions and methods to modulate faah for treatment of neurological disorders
WO2022020756A1 (en) * 2020-07-23 2022-01-27 John Mansell Compositions and methods for treating pain and anxiety disorders
CN119932015B (zh) * 2024-12-20 2025-11-25 中国科学院生物物理研究所 一种lncATRIG抑制剂及其在制备治疗胶质瘤的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7541359B2 (en) 2005-06-30 2009-06-02 Janssen Pharmaceutica N.V. N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase
US20070088073A1 (en) * 2005-10-19 2007-04-19 Allergan, Inc. Method for treating pain
US9920317B2 (en) * 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
EP2670245B1 (en) 2011-02-04 2015-09-09 The Scripps Research Institute Alpha-ketoheterocycles and methods of making and using
KR102079404B1 (ko) 2011-08-19 2020-02-19 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 메타-치환된 비페닐 말초 제한형 faah 억제제

Similar Documents

Publication Publication Date Title
Dong et al. New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors
JP2023543218A5 (https=)
Agarwal High-dose AAV gene therapy deaths
JP2004536103A5 (https=)
Shi et al. MiR-145 ameliorates neuropathic pain via inhibiting inflammatory responses and mTOR signaling pathway by targeting Akt3 in a rat model
JP2017529382A5 (https=)
JP2021512929A5 (https=)
Rojewska et al. PD98059 influences immune factors and enhances opioid analgesia in model of neuropathy
WO2018191450A3 (en) GENE THERAPY FOR A DEFICIENCY IN AADC
US20240108633A1 (en) Method for preventing or treating disease or condition associated with antitumor agent
US10864173B2 (en) Induced expression of brain derived neurotrophic factor (BDNF) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases
CA2368814A1 (en) Use of glucosylceramide synthesis inhibitors in therapy
MX2022006858A (es) Oligomeros antisentido para el tratamiento de condiciones y enfermedades.
WO2012016081A2 (en) Method and therapeutic for the treatment and regulation of memory formation
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
WO2025127968A3 (ru) Ингибитор ras-гтфазы и его применение для лечения онкологических заболеваний
Sun et al. The NLRP3-related inflammasome modulates pain behavior in a rat model of trigeminal neuropathic pain
WO2018140934A1 (en) Compositions and methods for hemoglobin production
MY207739A (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
MY200481A (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
Zhang et al. Macrophage migration inhibitory factor (MIF) promotes intervertebral disc degeneration through the NF‐κB pathway, and the MIF inhibitor CPSI‐1306 alleviates intervertebral disc degeneration in a mouse model
WO2022271699A3 (en) Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases
BR0317132A (pt) Métodos de diagnóstico e tratamento de doença pulmonar intersticial
US20210113654A1 (en) Methods and Compositions to Alleviate Vascular Permeability
WO2023235509A3 (en) Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases